ClinicalTrials.gg
RecruitingNCT06383468Updated Apr 25, 2024

A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of AK120 in Atopic Dermatitis, sponsored by Akeso. Recruiting at 59 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-25.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
40th of 190
420 · median 164
Started
2024
with 36 others
Phase 3
60 of 206
21 open now
Primary completion
2025-01
later than 9 of 81 live
Registered
110th of 206
by date
Lead sponsor
6 of 206
Akeso

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 40th largest by planned enrollment of the 190 interventional ones that give a count, is one of 37 that started in 2024, is one of 60 in phase 3, reaches primary completion later than 9 of the 81 other live ones, and was the 110th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 injection in the treatment of patients with moderate to severe atopic dermatitis.

Read the detailed description

This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 injection in the treatment of patients with moderate to severe atopic dermatitis. The entire study included a screening period, a double-blind controlled treatment period, a conversion and maintenance treatment period, and a safe follow-up period.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥18≤75 years old.
  2. Atopic dermatitis (AD) diagnosed at least 1 year before screening.
  3. Subject with eczema area and severity index (EASI) score ≥16, Investigator Global Assessment (IGA) score≥ 3, Body Surface Area (BSA) score ≥ 10% at screening and baseline.
  4. Previously received at least 4 weeks of moderate to strong or at least 2 weeks of strong local (TCS) treatment for AD before screening, with poor efficacy or intolerable

Exclusion criteria

Exclusion Criteria:

  1. Acute onset of AD within the first 4 weeks of randomization.
  2. Have participated in any clinical research on AK120 in the past
  3. Received systemic , /immunomodulatory drugs, phototherapy within the 4 weeks before randomization.
  4. Received treatment with other clinical research drugs (non-biological agents) within the first 4 weeks or 5 half-lives of randomization (whichever is longer)
  5. Received or planned to receive treatment within the 3 months before randomization or during the study period.
  6. Received allergen specific immunotherapy within the 3 months before randomization.
  7. Have a history of allergies to any component of AK120 and/or severe allergic reactions to monoclonal antibodies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    AK120 600mg/300mg

    AK120 600mg(first day) then 300mg Q2W subcutaneous injection thereafter until week 50.

    Drug: AK120

  • Placebo comparator
    Placebo/AK120 600mg to 300mg

    placebo Q2W SC, then AK120 600mg at week 16, thereafter change to AK120 300mg Q2W subcutaneous injection until week 50.

    Drug: AK120

Interventions

  • DrugAK120

    300mg Q2W subcutaneous injection thereafter until week 50.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who achieved (Eczema Area and Severity Index) EASI-75

    Percentage of patients in both treatment group and placebo group who achieved EASI 75 at week 16.

    Time frame: at week 16

Secondary outcomes

  1. Percentage of subjects who achieved 0/1 in the (Investigator's Global Assessment) IGA

    The percentage of patients in both treatment group and placebo group who achieved IGA 0/1 score at week 16.

    Time frame: at week 16

07

Study locations

59 of 59 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Jan 2025, 9 months later.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 9 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2024
First posted
Apr 25, 2024
StartEst.
Apr 30, 2024
Primary completionEst.
Jan 30, 2025
CompletionEst.
Jan 30, 2026
Last update
Apr 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06383468
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Apr 30, 2024 (estimated)
Primary completion
Jan 30, 2025 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Apr 25, 2024

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
+86 (0760) 8987 3999

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK120

Start the discussion